thalidomide has been researched along with rolipram in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Corral, LG; Muller, GW; Patterson, RT; Shire, MG; Stirling, DI; Wong, LM | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Jabaris, SS; Kodimuthali, A; Pal, M | 1 |
| Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Balk, KU; Byun, YS; Cho, JY; Lee, JH; Lee, SJ; Park, J; Park, JS; Park, MH; Son, HJ; Yoo, ES | 1 |
| Eigler, A; Endres, S; Loher, F | 1 |
| Abrahamsen, MS; Maheswaran, SK; Malazdrewich, C; Thumbikat, P | 1 |
| Argilés, JM; Busquets, S; López-Soriano, FJ | 1 |
| Brook, GA; Buss, A; Deumens, R; Geoghegan, L; Honig, WH; Joosten, EA; Kern, N; Koopmans, GC; Myint, AM; Noth, J | 1 |
| Andrews, M; Brennan, FM; Feldmann, M; Inglis, JJ; McCann, FE; Palfreeman, AC; Perocheau, DP; Schafer, P; Williams, RO | 1 |
| Carvalho, EM; Jesus, AR; Luna, T; Muniz, AL; Nascimento, M; Porto, MA; Santos, SB | 1 |
| Goldminz, AM; Gottlieb, AB; Kim, N; Kumar, N | 1 |
| Arias-Montaño, JA; Barragán-Ramírez, G; Fernández-Martínez, E; Mayén-García, C; Ortiz, MI; Ponce-Monter, H; Soria-Jasso, LE | 1 |
| Bergmann, C; Beyer, C; Distler, JHW; Kittan, N; Maier, C; Ramming, A; Schett, G; Weinkam, R | 1 |
4 review(s) available for thalidomide and rolipram
| Article | Year |
|---|---|
Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Topics: Asthma; Humans; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Pulmonary Disease, Chronic Obstructive | 2008 |
[Suppression of synthesis of tumor necrosis factor].
Topics: Animals; Arthritis, Rheumatoid; Crohn Disease; Humans; Inflammation; Interleukin-10; Phosphodiesterase Inhibitors; Rolipram; Signal Transduction; Thalidomide; Tumor Necrosis Factor-alpha | 2001 |
The pivotal role of cytokines in muscle wasting during cancer.
Topics: Animals; Anorexia; Antibodies; Cachexia; Cytokines; Humans; Models, Biological; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Pentoxifylline; Rolipram; Signal Transduction; Thalidomide; Transcription Factors | 2005 |
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Topics: Autoimmune Diseases; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Phosphodiesterase 4 Inhibitors; Rolipram; Thalidomide | 2013 |
12 other study(ies) available for thalidomide and rolipram
| Article | Year |
|---|---|
Thalidomide analogs and PDE4 inhibition.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Structure-Activity Relationship; Thalidomide; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.
Topics: | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-alpha production.
Topics: Animals; Mice; Models, Biological; Phosphodiesterase Inhibitors; Rolipram; Structure-Activity Relationship; Thalidomide; Tumor Necrosis Factor-alpha | 2000 |
Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxin-induced cytokine expression in bovine alveolar macrophages.
Topics: Animals; Anti-Inflammatory Agents; Cattle; Cells, Cultured; Cytokines; Dexamethasone; Exotoxins; Gene Expression Regulation; Imidazoles; Interleukin-1; Interleukin-8; Lipopolysaccharides; Macrophages, Alveolar; Mannheimia haemolytica; Pentoxifylline; Pyridines; RNA, Messenger; Rolipram; Tetrahydropapaveroline; Thalidomide; Tumor Necrosis Factor-alpha | 2004 |
Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury.
Topics: Animals; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Immunosuppressive Agents; Interleukin-1beta; Locomotion; Male; Myelin Basic Protein; Nerve Regeneration; Neurofilament Proteins; Phosphodiesterase Inhibitors; Psychomotor Performance; Rats; Rats, Inbred Lew; Recovery of Function; Rolipram; Spinal Cord Injuries; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha | 2009 |
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Phosphodiesterase 4 Inhibitors; Phosphodiesterase Inhibitors; Rolipram; Severity of Illness Index; Synovial Membrane; Thalidomide; Tumor Necrosis Factor-alpha | 2010 |
Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals.
Topics: Anti-Inflammatory Agents; Case-Control Studies; Colforsin; Female; HTLV-I Infections; Humans; Immunosuppressive Agents; Interferon-gamma; Leukocytes, Mononuclear; Male; Middle Aged; Pentoxifylline; Rolipram; Statistics, Nonparametric; Thalidomide; Tumor Necrosis Factor-alpha | 2011 |
Inhibition of Uterine Contractility by Thalidomide Analogs via Phosphodiesterase-4 Inhibition and Calcium Entry Blockade.
Topics: Adolescent; Adult; Calcium; Calcium Channel Blockers; Cells, Cultured; Cyclic AMP; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Models, Biological; Muscle Contraction; Myometrium; Phosphodiesterase 4 Inhibitors; Potassium; Pregnancy; Rolipram; Thalidomide; Young Adult | 2016 |
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Cyclic Nucleotide Phosphodiesterases, Type 4; Cytokines; Disease Models, Animal; DNA Topoisomerases, Type I; Fibroblasts; Fibrosis; Gene Expression; Graft vs Host Disease; Humans; Interleukin-13; Interleukin-6; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; RNA, Messenger; Rolipram; Scleroderma, Systemic; Skin; Thalidomide; Transforming Growth Factor beta1; Transforming Growth Factor beta2 | 2017 |